Complement Platform And Novo Nordisk Deal Will Reshape Long Term Outlook

Catalysts

About Omeros

Omeros is a biopharmaceutical company focused on complement biology, oncology and other high unmet medical needs through antibody, small molecule and biologic platforms.

What are the underlying business or industry changes driving this perspective?

• The expected closing of the Novo Nordisk transaction, with US$240 million upfront and up to US$2.1 billion in total potential consideration plus royalties, would remove near term debt obligations and extend the cash runway. This could ease funding risk and support future revenue and earnings growth from the remaining pipeline.
• Regulatory review of YARTEMLEA for TA TMA in the U.S. and Europe, along with established ICD 10 and CPT codes and a pending NTAP decision, positions Omeros to enter an approved treatment market where current options rely on off label use and have emerging safety concerns. This may support future product revenue and operating margin improvement if adoption occurs.
• A fully assembled and “launch ready” U.S. commercial organization, together with growing awareness of YARTEMLEA in the transplant community through peer reviewed publications, could shorten the ramp time from approval to commercial uptake. This may influence the timing and scale of revenue and the path to earnings break even.
• Retention of MASP 3 small molecule rights and a broader MASP 2 franchise, including Phase II ready OMS1029 and MASP 2 small molecules approaching IND enabling studies, keeps Omeros exposed to the growing use of targeted complement modulation in acute and chronic conditions. This may add future revenue streams and support gross margin expansion as the portfolio matures.
• The T CAT infectious disease platform and Oncotox oncology program, both advancing toward first in human studies and focused on areas such as multidrug resistant infections and AML, align with sustained demand for new anti infective and cancer therapies. If successfully developed, these programs could diversify revenue and reduce reliance on a single product for future earnings.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Omeros's revenue will grow by 211.1% annually over the next 3 years.
• Analysts assume that profit margins will shrink from 849.1% today to 8.0% in 3 years time.
• Analysts expect earnings to reach $23.8 million (and earnings per share of $1.12) by about June 2029, down from $84.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $61.1 million in earnings, and the most bearish expecting $-27.1 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 148.5x on those 2029 earnings, up from 7.5x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 14.7x.
• Analysts expect the number of shares outstanding to grow by 6.35% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Omeros is still loss making with a third quarter 2025 net loss of $30.9 million, $22.1 million on an adjusted basis, and cash and investments of $36.1 million, so any delay or shortfall in expected cash inflows, such as the Novo Nordisk upfront payment or later milestones, could pressure liquidity, increase financing needs and weigh on future earnings and net margins.
• The Novo Nordisk transaction for Zaltenibart restricts Omeros from pursuing MASP 3 antibodies and certain alternative pathway targets in several high priority indications. This could limit the long term scope of its complement franchise and reduce potential revenue and gross margin contribution from areas that now sit with Novo Nordisk rather than Omeros.
• The investment case leans heavily on successful approval and commercial uptake of YARTEMLEA in TA TMA. The FDA and EMA reviews are ongoing, labeling is uncertain, and the program relies on historical control data that has attracted regulatory scrutiny in other settings, so any regulatory setback or narrower than expected label could materially affect future product revenue and operating margins.
• New programs such as OMS1029, MASP 2 small molecules, PDE7, T CAT and Oncotox are all pre revenue and at varying early stages. The long development timelines to 2026 and 2027 for first in human studies and clinic entry create multi year execution and scientific risk that could delay or reduce prospective revenue diversification and keep earnings dependent on a single product.
• Noncash mark to market adjustments on embedded derivatives and the OMIDRIA royalty obligation have already introduced volatility into reported results, including an $8.8 million loss and a $22.3 million remeasurement benefit in the quarter. Continued accounting swings tied to stock price and royalty forecasts could obscure underlying performance and complicate analysis of trends in net income and earnings per share.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $33.0 for Omeros based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $297.9 million, earnings will come to $23.8 million, and it would be trading on a PE ratio of 148.5x, assuming you use a discount rate of 7.1%.
• Given the current share price of $8.67, the analyst price target of $33.0 is 73.7% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.